Kura Oncology reports 94% 12-month survival in KOMET-007 trial of ziftomenib plus 7+3 in newly diagnosed NPM1-mutant AML

Kura Oncology, Inc.

Kura Oncology, Inc.

KURA

0.00
  • Kura Oncology reported long-term results from the Phase 1/2 KOMET-007 trial of ziftomenib with standard intensive chemotherapy in newly diagnosed AML.
  • Results will be presented at the European Hematology Association 2026 Congress.
  • The single-arm study showed high remission rates, deep molecular responses, durable benefit, favorable survival trends, and manageable safety across key genetic subtypes.
  • Data supported confidence in the ongoing Phase 3 KOMET-017 registrational program testing the same approach in frontline AML.
  • Ziftomenib remains FDA-cleared only as monotherapy in relapsed or refractory NPM1-mutant AML; the frontline combination remains investigational.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.